Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the feasibility of the Mediracer® NCS device in early detection of CIPN in patients receiving potentially neurotoxic substance (vincristine, oxaliplatin or docetaxel) as a part of their chemotherapy regimen.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mediracer® NCS | Device | A point-of-care, hand-held nerve conduction device |
| Measure | Description | Time Frame |
|---|---|---|
| Nerve conductivity | Nerve conductivity of n. medianus and ulnaris by Mediracer® NCS | 6 weeks |
| Nerve conductivity | Nerve conductivity of n. medianus and ulnaris by Mediracer® NCS | 12 weeks |
| Nerve conductivity | Nerve conductivity of n. medianus and ulnaris by Mediracer® NCS | 18 weeks |
| Nerve conductivity | Nerve conductivity of n. medianus and ulnaris by Mediracer® NCS | 24 weeks |
| Neuropathy related pain | Neuropathy related pain according to NPSI-assessment | 6 weeks |
| Neuropathy related pain | Neuropathy related pain according to NPSI-assessment | 12 weeks |
| Neuropathy related pain | Neuropathy related pain according to NPSI-assessment | 18 weeks |
| Neuropathy related pain | Neuropathy related pain according to NPSI-assessment | 24 weeks |
| Chemotherapy induced peripheral neuropathy (CIPN) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients receiving neurotoxic chemotherapy (oxaliplatin, vincristine, or docetaxel) as cancer treatment.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oulu University Hospital | Oulu | Finland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
CIPN assessed by EORTC QLQ-CIPN20 questionnaire |
| 6 weeks |
| Chemotherapy induced peripheral neuropathy (CIPN) | CIPN assessed by EORTC QLQ-CIPN20 questionnaire | 12 weeks |
| Chemotherapy induced peripheral neuropathy (CIPN) | CIPN assessed by EORTC QLQ-CIPN20 questionnaire | 18 weeks |
| Chemotherapy induced peripheral neuropathy (CIPN) | CIPN assessed by EORTC QLQ-CIPN20 questionnaire | 24 weeks |
| Frequency of CIPN by CTCAE | Frequency of CIPN by CTCAE | 6 weeks |
| Frequency of CIPN by CTCAE | Frequency of CIPN by CTCAE | 12 weeks |
| Frequency of CIPN by CTCAE | Frequency of CIPN by CTCAE | 18 weeks |
| Frequency of CIPN by CTCAE | Frequency of CIPN by CTCAE | 24 weeks |